Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevention Bio

- PMLiVE

BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m

Both companies will leverage their autologous CAR-T cell therapy programmes

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE

FDA approves two cell-based gene therapies for sickle cell disease

Vertex/CRISPR and bluebird bio’s gene therapies have been approved to treat patients aged 12 years and older

- PMLiVE

BioNTech acquires right to Biotheus’ bispecific antibody candidate in deal worth over $1bn

PM8002 is currently being evaluated in phase 2 studies in patients with advanced solid tumours

- PMLiVE

bluebird bio presents positive results for inherited blood disorder gene therapies

The company’s sickle cell disease therapy was accepted for FDA priority review earlier this year

- PMLiVE

bluebird bio to sell FDA priority review voucher for $103m

The company previously sold its second voucher to Bristol Myers Squibb for $95m

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

- PMLiVE

BioNTech and Duality Biologics add third ADC candidate to oncology partnership

The companies announced the original agreement covering two antibody-drug conjugates in April

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links